Literature DB >> 24131106

Genotype, echocardiography, and survival in familial transthyretin amyloidosis.

Adelaide M Arruda-Olson1, Steven R Zeldenrust, Angela Dispenzieri, Morie A Gertz, Fletcher A Miller, Suzette J Bielinski, Kyle W Klarich, Christopher G Scott, Martha Grogan.   

Abstract

BACKGROUND: More than 100 transthyretin (TTR) variants have been identified which cause familial systemic amyloidosis. It has been increasingly recognized that TTR variants of familial systemic amyloidosis contribute to clinical characteristics, including age at diagnosis, cardiac phenotype and survival.
METHODS: Two hundred and eighty-two patients who underwent genotyping for TTR variants were identified. This study focused on 116 patients representing the three most common TTR variants; T60A (n = 58), V30M (n = 37) and V122I (n = 21). The remaining subjects (n = 61) were distributed amongst 33 different genotypes and excluded from analysis.
RESULTS: Age at diagnosis was similar by genotype. Septal, posterior wall thickness, right ventricular systolic pressure and left ventricular mass index were greater and LVEF lower in the V122I subgroup. At mean follow up of 3.0 ± 2.6 years there were 62 deaths. V30M patients had the best survival. Survival was similar between V122I and T60A patients. The association of genotype with mortality persisted after adjustments for clinical variables.
CONCLUSIONS: For familial TTR amyloidosis cardiac involvement is frequent and mortality high for T60A, V122I and V30M genotypes. Specific genotype predicted severity of phenotypic expression as measured by echocardiography and survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24131106     DOI: 10.3109/13506129.2013.845745

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  13 in total

Review 1.  Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.

Authors:  Omar K Siddiqi; Frederick L Ruberg
Journal:  Trends Cardiovasc Med       Date:  2017-07-13       Impact factor: 6.677

Review 2.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

Review 3.  The clinical approach to autonomic failure in neurological disorders.

Authors:  Eduardo E Benarroch
Journal:  Nat Rev Neurol       Date:  2014-05-27       Impact factor: 42.937

Review 4.  FAP neuropathy and emerging treatments.

Authors:  David Adams; Marie Théaudin; Cecile Cauquil; Vincent Algalarrondo; Michel Slama
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

Review 5.  Novel drugs targeting transthyretin amyloidosis.

Authors:  Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 6.  Heart transplantation in cardiac amyloidosis.

Authors:  Matthew Sousa; Gregory Monohan; Navin Rajagopalan; Alla Grigorian; Maya Guglin
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 7.  Current and future circulating biomarkers for cardiac amyloidosis.

Authors:  Marco Luciani; Luca Troncone; Federica Del Monte
Journal:  Acta Pharmacol Sin       Date:  2018-05-17       Impact factor: 6.150

8.  Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review.

Authors:  Amandeep Goyal; Shubham Lahan; Tarun Dalia; Sagar Ranka; Venugopal Brijmohan Bhattad; Ronak R Patel; Zubair Shah
Journal:  Heart Fail Rev       Date:  2021-03-25       Impact factor: 4.214

Review 9.  Imaging-Guided Treatment for Cardiac Amyloidosis.

Authors:  Adam Ioannou; Rishi Patel; Julian D Gillmore; Marianna Fontana
Journal:  Curr Cardiol Rep       Date:  2022-05-07       Impact factor: 3.955

Review 10.  Cardiac Amyloidosis: Multimodal Imaging of Disease Activity and Response to Treatment.

Authors:  Rishi K Patel; Marianna Fontana; Frederick L Ruberg
Journal:  Circ Cardiovasc Imaging       Date:  2021-06-15       Impact factor: 8.589

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.